Cross-border life sciences and health care M&A is experiencing a shift in value allocation. In advanced carve-outs, regulatory dossiers, Good Practice (GxP) records, and product registration, robust documentation is paramount, and regulatory data migration is a critical path to successful separation and post-closing operability.

A decade ago, data migration was peripheral; today, it drives many technical SPA provisions, including chain of custody, extraction formats, seller-controlled scope, buyer-funded separation, and precise sequencing with product registration transfers. Contracts acknowledge that regulatory data integrity is central to enterprise value and a precondition for lawful post-closing commercialization.

This shift is driven by converging regulatory forces. Data volumes have exploded under the Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), AI-enabled evidence requirements, and expanded GxP documentation. Valuation has followed: in many carve-outs, it hinges on dossier integrity and timely registration transfers. Delays in transferring product registration data can shut down market access for months, absent effective transitional distribution arrangements.

Therefore, SPAs increasingly reframe data as an independent class of transferred asset – often defined as "Transferred Records" – with bespoke mechanics, regulated timing windows, and seller-controlled formats. Data is increasingly primary rather than ancillary to a transitional services agreement (TSA) stream.

Risk allocation is becoming more explicit in M&A, as sellers seek the right to extract data in flat files or portable documents at their discretion, and buyers often absorbing separation and integration costs. Chain-of-custody is becoming a defined contractual event, typically with a predetermined verification period. It is less common for warranties to exceed regulatory minimums, as operational and compliance risks can shift to the buyer.

Critically, data migration is more often contractually tied to product registration transfers, with delivery windows aligned to local regulatory requirements and hard stop dates. The regulatory file, not the closing certificate, is frequently the deliverable that determines whether carved out products can be lawfully marketed post-closing in target jurisdictions.

From a GxP perspective, data integrity is not synonymous with technical completeness or file transfer. Regulatory data must remain usable, inspectable, and defensible throughout migration. Flat-file extractions or static document sets may preserve content, but they routinely strip away metadata, audit trails, system logic, and contextual information essential to compliance with ALCOA+ principles.

In 2026, leading life sciences and health care transactions may be defined less by asset schedules, and more by regulatory information ecosystems. Data migration provisions, once buried in TSAs, increasingly shape valuation, execution risk, and compliance.